Additional research is needed to determine if this therapy could actually protect or regenerate beta cells
Beyond their metabolic effects, GLP-1 RAs have demonstrated cardiovascular and renal benefits in large outcome trials, including reductions in major adverse cardiovascular events (MACE) and attenuation of albuminuria progression ( Table 1 , renal eligibility criteria across landmark GLP-1 RA cardiovascular and kidney outcome trials consistently excluded dialysis-dependent patients, resulting in a persistent lack of randomized evidence in this high-risk population
Laboratories should use appropriate personal protective equipment and maintain accurate documentation throughout storage, preparation, handling, and disposal of peptide materials
The relevant clinical conversation, when it becomes one, is for patients who plateau on existing therapy or who would otherwise be candidates for bariatric surgery a population for whom retatrutide's responder rates start to look like a genuine alternative
You should be committed to making lifestyle changes alongside medication
In clinical practice, side effects often depend on the starting dose, how quickly the dose is increased, meal size, hydration, and sensitivity to delayed stomach emptying